A detailed history of Vident Advisory, LLC transactions in Genmab A/S stock. As of the latest transaction made, Vident Advisory, LLC holds 8,388 shares of GMAB stock, worth $172,625. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,388
Holding current value
$172,625
% of portfolio
0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.84 - $28.48 $199,969 - $238,890
8,388 New
8,388 $205 Million
Q3 2023

Feb 21, 2024

BUY
$35.27 - $42.24 $291,400 - $348,986
8,262 New
8,262 $291 Million
Q3 2023

Nov 14, 2023

BUY
$35.27 - $42.24 $291,400 - $348,986
8,262 New
8,262 $291 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.